Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
QurAlis is a biotechnology company that creates precision medicine solutions to cure ALS and FTD.
Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders.
etherna develops mRNA and lipid nanoparticle solutions.
INNOVO by Atlantic Therapeutics is a medical technology firm that develops pelvic floor muscle strengthening and nerve stimulation products.
Visus Therapeutics is a clinical-stage company developing innovative medicines.
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.
Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solution.
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.
Luxendo develops and manufactures proprietary light-sheet fluorescence microscopy instruments.
Sapiens is a medical device company that delivers solutions for deep brain stimulation therapy.
EQT Life Sciences has invested in 82 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
EQT Life Sciences's top investment sectors include Biotechnology, Therapeutics, Health Care, Medical, Genetics. The firm invests across 15 different industry categories.
Among tracked funding rounds, Amolyt Pharma received $138.6M in a Series C round. EQT Life Sciences's total known invested capital is $4.0B.
EQT Life Sciences's average investment size is $53.3M across its portfolio of 82 companies.
Recent EQT Life Sciences portfolio additions include QurAlis, Amolyt Pharma, etherna immunotherapies, INNOVO by Atlantic Therapeutics, Visus Therapeutics. These companies were founded in 2020 or later.